The study is designed to assess the effectiveness of a panel of Neogenix monoclonal antibodies as diagnostic markers for colorectal and pancreatic cancer. The diagnostic properties of these antibodies will be evaluated in 120 pancreatic and colon cancer patients. The trial is scheduled to begin in December 2008.
Philip Arlen, Neogenix’s president and chief medical officer, said: “Since their discovery, we have observed that our antibodies have both therapeutic and diagnostic properties. While our efforts thus far have focused on developing the therapeutic potential for our first antibody, NPC-1C, the initiation of this trial marks the expansion of our focus to include diagnostics.
“Our goal is to develop a new generation of serum diagnostics which will make an important contribution to the earlier diagnosis and improvement in the management of a number of common malignancies.”